Bryan Johnson· Author
Clinical outcomes Psilocybin activates 5-HT2A receptors to reduce neuroinflammation, protect neurons, and may slow neurodegeneration.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Clinical outcomes Psilocybin activates 5-HT2A receptors to reduce neuroinflammation, protect neurons, and may slow neurodegeneration.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Psychedelics including psilocybin, LSD, and DMT all mitigate neuroinflammation by activating the 5-HT2A receptors leading to a decrease in pro-inflammatory cytokines, microglial modulation and a shift from neurotoxic to neuroprotective metabolites.